or Try an Advanced Search...

    Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 21.53 4.87% 1.00
    SNDX closed up 4.87 percent on Monday, July 1, 2024, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical SNDX trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Older End-of-Day Signals for SNDX ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 6 hours ago
    Up 1 ATR about 7 hours ago
    60 Minute Opening Range Breakout about 8 hours ago
    Rose Above Previous Day's High about 10 hours ago
    Rose Above Upper Bollinger Band about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    SNDX Chart by TradingView
    Basic chart:

    Profile

    Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

    Is SNDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 Syndax: Gearing Up For Launches
    Jun 14 Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
    Jun 10 Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
    Jun 6 Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
    Jun 5 Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
    May 29 Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    May 15 Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
    May 12 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
    May 9 Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
    May 9 Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
    See more SNDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.34
    52 Week Low 11.23
    Average Volume 1,068,903
    200-Day Moving Average 19.31
    50-Day Moving Average 20.55
    20-Day Moving Average 19.81
    10-Day Moving Average 19.99
    Average True Range 0.89
    RSI (14) 61.98
    ADX 15.2
    +DI 30.32
    -DI 15.56
    Chandelier Exit (Long, 3 ATRs) 19.03
    Chandelier Exit (Short, 3 ATRs) 21.32
    Upper Bollinger Bands 21.07
    Lower Bollinger Band 18.55
    Percent B (%b) 1.18
    BandWidth 12.72
    MACD Line 0.02
    MACD Signal Line -0.20
    MACD Histogram 0.2278
    Fundamentals Value
    Market Cap 1.83 Billion
    Num Shares 84.8 Million
    EPS -2.59
    Price-to-Earnings (P/E) Ratio -8.31
    Price-to-Sales 12.67
    Price-to-Book 5.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.66
    Resistance 3 (R3) 23.48 22.59 23.31
    Resistance 2 (R2) 22.59 22.05 22.68 23.19
    Resistance 1 (R1) 22.06 21.71 22.33 22.24 23.07
    Pivot Point 21.17 21.17 21.30 21.26 21.17
    Support 1 (S1) 20.64 20.63 20.91 20.82 19.99
    Support 2 (S2) 19.75 20.29 19.84 19.87
    Support 3 (S3) 19.22 19.75 19.76
    Support 4 (S4) 19.40